CoChat

Role of Hepatic Transporters in the Disposition and Hepatotoxicity of a HER2 Tyrosine Kinase Inhibitor CP-724,714

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

CP-724,714, a potent and selective orally active HER2 tyrosine kinase inhibitor, was discontinued from clinical development due to unexpected hepatotoxicity in cancer patients. Based on the clinical manifestation of the toxicity, CP-724,714 likely exerted its hepatotoxicity via both hepatocellular injury and hepatobiliary cholestatic mechanisms. The direct cytotoxic effect, hepatobiliary disposition of CP-724,714, and its inhibition of active canalicular transport of bile constituents were evaluated in established human hepatocyte models and in vitro transporter systems. CP-724,714 exhibited direct cytotoxicity using human hepatocyte imaging assay technology with mitochondria identified as a candidate organelle for its off-target toxicity. Additionally, CP-724,714 was rapidly taken up into human hepatocytes, partially via an active transport process, with an uptake clearance approximately fourfold higher than efflux clearance. The major human hepatic uptake transporter, OATP1B1, and efflux transporters, multidrug resistance protein 1 (MDR1) and breast cancer resistance protein, were involved in hepatobiliary clearance of CP-724,714. Furthermore, CP-724,714 displayed a concentration-dependent inhibition of cholyl-lysyl fluorescein and taurocholate (TC) efflux into canaliculi in cryopreserved and fresh cultured human hepatocytes, respectively. Likewise, CP-724,714 inhibited TC transport in membrane vesicles expressing human bile salt export pump with an IC(50) of 16 microM. Finally, CP-724,714 inhibited the major efflux transporter in bile canaliculi, MDR1, with an IC(50) of approximately 28 microM. These results suggest that inhibition of hepatic efflux transporters contributed to hepatic accumulation of drug and bile constituents leading to hepatocellular injury and hepatobiliary cholestasis. This study provides likely explanations for clinically observed adverse liver effects of CP-724,714.

Overview

Integrity signals

Registry

Crossref · 10.1093/toxsci/kfp033

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

See all 84

Metadata

Authors
Feng, B., Xu, J. J., Bi, Y.-A., Mireles, R., Davidson, R., Duignan, D. B., Campbell, S., Kostrubsky, V. E., Dunn, M. C., Smith, A. R., & Wang, H. F.
Affiliations
  • Pfizer (United States) (US)
  • Washington University in St. Louis (US)
Venue
Toxicological Sciences
Published
2009-02-17
Volume
108
Issue
2
Pages
492-500
ISSN
  • 1096-0929 (ISSN-L)
  • 1096-6080
OpenAlex
W2144377055
Cited by
80
References
32
Citations by year
2026: 1 · 2025: 2 · 2024: 2 · 2023: 3 · 2022: 1 · 2021: 2 · 2020: 2 · 2019: 7 · 2018: 3 · 2017: 6 · 2016: 7 · 2015: 7 · 2014: 3 · 2013: 11 · 2012: 10
FWCI
3.83
Type
journal article
Language
en
Open access
closed
Locations
  • Toxicological Sciences (publishedVersion)
  • PubMed (publishedVersion)
Funders
Pfizer
Topics
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Keywords
trastuzumab emtansine, HER2 tyrosine kinase inhibitor, hepatotoxicity, drug disposition, hepatic transporters, OATP1B1, MDR1, ABCG2, bile salt export pump, hepatocyte injury, drug-induced liver injury, mitochondrial toxicity, drug repurposing
MeSH terms
ATP Binding Cassette Transporter, Subfamily G, Member 2, Multidrug Resistance-Associated Protein 2, Bile, Bile Acids and Salts, Calcium, Carrier Proteins, Cells, Cultured, Enzyme Inhibitors, Fluoresceins, Humans, Liver, Membrane Potentials, Neoplasm Proteins, Quinazolines, ATP Binding Cassette Transporter, Subfamily B, ATP-Binding Cassette Transporters, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, ATP Binding Cassette Transporter, Subfamily B, Member 1, Hepatocytes, Liver-Specific Organic Anion Transporter 1, Multidrug Resistance-Associated Proteins, ATP-Binding Cassette, Sub-Family C Proteins, Mitochondrial Membranes, Chemical and Drug Induced Liver Injury

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.